[August 29, 2016]

Global Neuropathic Pain Therapeutics Pipeline Review H1 2016 - 121 Companies & Drug Profiles - Research and Markets

Research and Markets has announced the addition of the "Neuropathic Pain - Pipeline Review, H1 2016" report to their offering.

Neuropathic Pain pipeline therapeutics constitutes close to 236 molecules. Out of which approximately 202 molecules are developed by Companies and remaining by the Universities/Institutes. Our latest report Neuropathic Pain - Pipeline Review, H1 2016, outlays comprehensive information on the therapeutics under development for Neuropathic Pain, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

Neuropathic Pain Neuropathic pain, or neuralgia, is a condition in which the sensory system is affected. It is commonly accompanied by tissue injury. The nerve fibres could be damaged resulting in the generation of abnormal signals. Neuropathic pain is also exhibited along with many other diseases. The symptoms might include shooting pain and numbness. Several factors are involved in causing neuropathic pain however there seems to be no specific reason. Trauma, kidney disease, alcoholism, infections, stress etc may lead to painful symptoms. The condition may be controlled by the use of medications and psychological therapies. The molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 7, 28, 28, 1, 1, 114, 20 and 2 respectively. Similarly, the Universities portfolio in Phase I Preclinical and Discovery stages comprises 1, 32 and 1 molecules, respectively.

Furthermore, this report also reviews of key players involved in therapeutic development for Neuropathic Pain and features dormant and discontinued projects.

Key Topics Covered:

1. Introduction
2. Neuropathic Pain Overview
3. Therapeutics Development
4. Pipeline Products for Neuropathic Pain - Overview
5. Pipeline Products for Neuropathic Pain - Comparative Analysis
6. Neuropathic Pain - Therapeutics under Development by Companies
7. Neuropathic Pain - Therapeutics under Investigation by Universities/Institutes
8. Neuropathic Pain Products Glance
9. Late Stage Products
10. Clinical Stage Products
11. Early Stage Products
12. Neuropathic Pain - Products under Development by Companies
13. Neuropathic Pain - Products under Investigation by Universities/Institutes
14. Neuropathic Pain - Companies Involved in Therapeutics Development

• 2-BBB Medicines BV
• AbbVie Inc.
• Achelios Therapeutics, Inc.
• Adynxx, Inc.
• Aestus Therapeutics, Inc.
• Affectis Pharmaceuticals AG
• Amura Holdings Limited
• AnaBios Corporation
• Anavex Life Sciences Corp.
• AngioChem Inc.
• APT (News - Alert) Therapeutics, Inc.
• Arena Pharmaceuticals, Inc.
• Asahi Kasei Pharma Corp.
• Astellas Pharma Inc.
• AstraZeneca Plc
• BCI Pharma
• BCN (News - Alert) Peptides, S.A.
• Benitec Biopharma Limited
• BioDelivery Sciences International, Inc.
• Biogen, Inc.
• BioLineRx, Ltd.
• Biomar Microbial Technologies
• Bionomics Limited
• Bristol-Myers Squibb Company
• Can-Fite BioPharma Ltd.
• Cara Therapeutics, Inc.
• Catalyst Biosciences, Inc.
• Cavion LLC
• Centrexion Corporation
• Cerecor Inc.
• Chromocell Corporation
• Circuit Therapeutics, Inc.
• CLL Pharma
• Colby Pharmaceutical Company
• ContraVir Pharmaceuticals, Inc.

For more information about this report visit http://www.researchandmarkets.com/research/mxxwnm/neuropathic_pain

Related Topics: Analgesics

View source version on businesswire.com: http://www.businesswire.com/news/home/20160829005772/en/

[ Back To TMCnet.com's Homepage ]